[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cisplatin-induced-ototoxicity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cisplatin-induced-ototoxicity":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100620986","phase-2-protective-effect-of-acetylcysteine-against-cisplatinum-induced-ototoxicity-a-randomized-controlled-trial-100620986",false,"NCT07364747","Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged between 18 and 70 years\n* Patients scheduled to receive high-dose cisplatin-based chemotherapy regimens with a projected cumulative cisplatin dose of \\> 200 mg\u002Fm2 and each dose \\> 50 mg\u002Fm2\n* Patients may receive concurrent chemotherapy with non-ototoxic agents\n* Patients may receive concurrent radiation therapy to the skull base, provided the radiation dose does not exceed the toxic threshold for ototoxicity\n* Patients receiving an appropriate antiemetic regimen consisting of Olanzapine or Neurokinin-1 (NK1) receptor antagonists\n* Patients receiving medical treatment at Siriraj Hospital.\n\nExclusion Criteria:\n\n* Patients diagnosed with Nasopharyngeal Carcinoma (CA nasopharynx).\n* Patients with a history of head and neck radiation therapy where the radiation dose to the cochlea exceeded 9 Gy or the dose to the eustachian tube exceeded 50 Gy on both sides.\n* Patients who have received N-acetylcysteine (NAC) within 2 weeks prior to the start of the study.\n* Patients who have received other ototoxic drugs within 2 weeks prior to or during the study, including but not limited to:\n\nAminoglycoside antibiotics, Vancomycin, Loop diuretics (e.g., Furosemide), High-dose Aspirin, Antimalarial drugs (e.g., Quinine)\n\n\\- Patient with a known allergy or hypersensitivity to acetylcysteine.","ALL","18 Years","70 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to evaluate the efficacy of N-acetylcysteine (NAC) in preventing cisplatin-induced ototoxicity in patients receiving cisplatin-based chemotherapy. Cisplatin is a highly effective chemotherapeutic agent but often leads to permanent hearing loss (ototoxicity) as a significant side effect. This study investigates whether the administration of NAC as an otoprotective agent can reduce or prevent the decline in hearing sensitivity, particularly at extended high frequencies, as measured by audiometry and distortion product otoacoustic emissions (DPOAE).",[26,27,28,29],"Cisplatin-induced Ototoxicity","Sensorineural Hearing Loss","Ototoxicity","Ototoxicity, Drug-Induced",[26,27,28],"RECRUITING","2026-01-16",{"date":34,"type":35},"2026-01-23","ACTUAL",{"date":37,"type":35},"2024-12-23",{"date":39,"type":20},"2027-03-31",{"name":41,"class":42},"Siriraj Hospital","OTHER"]